Pathology-guided treatment of rectal cancer

Submission date Prospectively registered Recruitment status 06/04/2000 No longer recruiting [] Protocol [] Statistical analysis plan Registration date Overall study status 06/04/2000 Completed [X] Results [] Individual participant data Last Edited Condition category 17/10/2018 Cancer

Plain English summary of protocol

Not provided at time of registration

Study website

http://www.ctu.mrc.ac.uk/studies/CR07.asp

Contact information

Type(s)

Scientific

Contact name

Dr David Sebag-Montefiore

Contact details

Leeds Cancer Centre Cookridge Hospital Hospital Lane Leeds United Kingdom LS16 6QB

Additional identifiers

EudraCT/CTIS number

IRAS number

 ${\bf Clinical Trials. gov\ number}$

NCT00003422

Secondary identifying numbers

CR07

Study information

Scientific Title

Pathology-guided treatment of rectal cancer: a randomised controlled trial

Study objectives

In inoperable rectal cancer: are local recurrence-free survival rates and quality of life optimised by giving all patients short course pre-operative radiotherapy, or is it a preferable option to give post-operative chemoradiotherapy only to those at high risk of recurrence (i.e. with involved margins following surgery)?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Rectal cancer

Interventions

- 1. One group receives a short course pre-operative radiotherapy followed by surgery
- 2. The other group receives surgery followed by postoperative chemo-radiotherapy

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Local recurrence (as defined using an algorithm designed for the trial).

Secondary outcome measures

- 1. Local recurrence-free survival
- 2. Overall survival
- 3. Time to appearance of distant metastases
- 4. Disease-free survival
- 5. Morbidity
- 6. Quality of life
- 7. Economic implications

Overall study start date

01/02/1998

Completion date

05/08/2005

Eligibility

Key inclusion criteria

- 1. Histologically confirmed adenocarcinoma of the rectum
- 2. Considered potentially operable
- 3. No evidence of metastases
- 4. Patient considered fit to receive either arm of the trial
- 5. No concurrent uncontrolled medical illness
- 6. No previous or current malignant disease likely to interfere with treatment or comparisons
- 7. Informed consent obtained

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

1350

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/02/1998

Date of final enrolment

05/08/2005

Locations

Countries of recruitment

Canada

England

United Kingdom

Study participating centre Leeds Cancer Centre Leeds United Kingdom LS16 6QB

Sponsor information

Organisation

Medical Research Council (MRC) (UK)

Sponsor details

20 Park Crescent London United Kingdom W1B 1AL +44 (0)20 7636 5422 clinical.trial@headoffice.mrc.ac.uk

Sponsor type

Research council

Website

http://www.mrc.ac.uk

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council (MRC) (UK)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Plain English results				No	Yes
Results article	Initial results:	07/03/2009		Yes	No
Results article	Prospective study results:	07/03/2009		Yes	No